青少年和年轻成人晚期实体瘤患者参与I期临床试验的临床结局
该研究分析了2002至2016年间在皇家马斯登医院药物开发部接受I期临床试验的219例青少年和年轻成人(AYA)晚期实体瘤患者,占总I期试验患者的8%。主要肿瘤类型为妇科肿瘤(25%)和肉瘤(18%)。客观缓解率为12%,6个月临床获益率为22%,中位总生存期为7.5个月(95%CI 6.3-9.5),2年总生存率为11%。
要点
- AYA患者占I期试验人群的8%,妇科肿瘤和肉瘤最常见。
- 客观缓解率12%,6个月临床获益率22%,中位OS 7.5个月。
- 36%的缓解患者基于胚系或体细胞基因异常匹配了I期试验。
核心结论
- AYA晚期实体瘤患者参与I期试验总体获益有限,但部分患者可获得持久缓解。
研究设计与样本
- 回顾性分析2002-2016年皇家马斯登医院药物开发部I期临床试验中219例AYA(15-39岁)晚期实体瘤患者。
主要发现
- 客观缓解率为12%,6个月临床获益率为22%。
- 中位总生存期为7.5个月(95%CI 6.3-9.5),2年总生存率为11%。
- 3/4级毒性发生率为26%。
- 36%的缓解患者基于胚系或体细胞基因异常匹配了I期试验。
临床怎么用
- AYA患者可考虑参与I期临床试验,尤其存在可靶向分子异常时。
- 应关注AYA患者的遗传性癌症综合征和家族史,以指导治疗选择。
局限性
- 回顾性研究,单中心数据,样本量有限。
- 分子特征分析仅部分患者(n=45)可用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM: To study the outcome of AYA patients in phase I clinical trials. METHODS: Clinical trial data of AYAs (defined as aged 15-39 years at diagnosis) treated at the Drug Development Unit, Royal Marsden Hospital, between 2002 and 2016, were analysed. RESULTS: From a prospectively maintained database of 2631 patients treated in phase I trials, 219 AYA patients (8%) were identified. Major tumour types included gynaecological cancer (25%) and sarcoma (18%). Twenty-five (11%) had a known hereditary cancer syndrome (most commonly BRCA). Molecular characterisation of tumours (n = 45) identified mutations most commonly in TP53 (33%), PI3KCA (18%) and KRAS (9%). Therapeutic targets of trials included DNA damage repair (16%), phosphoinositide 3-kinase (PI3K) (16%) and angiogenesis (16%). Grade 3/4 toxicities were experienced in 26% of patients. Of the 214 evaluable patients, objective response rate was 12%, with clinical benefit rate at 6 months of 22%. Median overall survival (OS) was 7.5 months (95% confidence interval: 6.3-9.5), and 2-year OS was 11%. Of patients with responses, 36% were matched to phase I trials based on germline or somatic genetic aberrations. CONCLUSION: We describe the outcome of the largest cohort of AYA patients treated in phase I trials. A subgroup of these patients demonstrates benefit, with several durable responses beyond 2 years. A sizeable proportion of AYA patients have cancer syndromes, significant family history or somatic molecular aberrancies which may influence novel therapeutic treatment options.
引用
- Sundar R, McVeigh T, Dolling D, et al. Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. Eur J Cancer. 2018. PMID: 30025230. doi:10.1016/j.ejca.2018.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。